Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 9.15
Day High 9.42
Open:9.26
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The Company operates in one business segment namely, development of drug candidates for health solutions.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

BELLUS Health Announces Pricing of US$70 Million Public Offering in Canada and the United States
- BusinessWire - Thu Sep 5, 6:00AM CDT
BusinessWire - CMTX
Thu Sep 5, 6:00AM CDT
In connection with its previously announced public offering of common shares in Canada and the United States (the "Offering"), BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Cowen and Guggenheim Securities, as joint book-running managers, Baird, as lead manager, and Bloom Burton Securities, as co-manager (collectively, the "Underwriters"). The Underwriters have agreed to purchase 9,859,155 common shares at a price of US$7.10 per common share (C$9.40 per common share) for aggregate gross proceeds to the Company of US$70 million. The Offering was upsized from US$60 million to US$70 million. Closing of the Offering is expected to occur on September 9, 2019, subject to the satisfaction of customary closing conditions. In addition, the Underwriters have been granted a 30-day over-allotment option following the date hereof to purchase up to an additional 1,478,873 common shares from the Company.
BELLUS Health Announces the Launch of a US$60 Million Public Offering of Common Shares in Canada and the United States and the Filing of an Application to List Its Common Shares on Nasdaq
- BusinessWire - Tue Sep 3, 7:05AM CDT
BusinessWire - CMTX
Tue Sep 3, 7:05AM CDT
BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX: BLU), announced today the filing of a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 26, 2019 (the "Base Prospectus") in connection with a proposed US$60 million public offering of its common shares (the "Offering"), and the filing of an application to list its common shares on the Nasdaq Global Market ("Nasdaq") in the United States under the ticker "BLU". Trading of the Company's common shares is expected to commence on the Nasdaq following the pricing of the Offering. The Supplement was filed with each of the securities regulatory authorities in the provinces of Canada. The Supplement and accompanying Base Prospectus were also filed with the U.S. Securities and Exchange Commission (the "SEC") as part of a registration statement on Form F-10, as it may be amended from time to time (the "Registration Statement"), in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. The Company intends to use the net proceeds of the Offering primarily to fund research and development activities, general and administrative expenses, working capital needs and other general corporate purposes, as set out in the Supplement.
BELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
- BusinessWire - Mon Aug 26, 6:00AM CDT
BusinessWire - CMTX
Mon Aug 26, 6:00AM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of Dr. Catherine Bonuccelli, MD to the role of Chief Medical Officer. Dr. Bonuccelli is a pediatric pulmonologist that brings over 20 years of pharmaceutical experience with significant expertise in clinical and product development of respiratory and non-respiratory products.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 7.37 +25.24% increase
on 11/13/19
Period Open:8.10
Price movement based on the high, low and last over the given period.
9.67 -4.55% decrease
on 12/09/19
+1.13 (+13.95%) increase
since 11/12/19
3-Month 7.37 +25.24% increase
on 11/13/19
Period Open:9.60
Price movement based on the high, low and last over the given period.
9.97 -7.42% decrease
on 09/20/19
-0.37 (-3.85%) decrease
since 09/12/19
52-Week 2.91 +217.18% increase
on 01/30/19
Period Open:3.42
Price movement based on the high, low and last over the given period.
11.20 -17.59% decrease
on 08/22/19
+5.81 (+169.88%) increase
since 12/12/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies